Spanish Life Sciences Stock News

Indra Sistemas (BME:IDR) has drawn attention after publishing its half year 2026 earnings, reporting sales of €3,258.96 million and net income of €219.24 million, along with a slight increase in earnings per share from continuing operations. See our latest analysis for Indra Sistemas. The latest earnings update comes as Indra Sistemas trades at €56.8, with a 1-day share price return of 1.10% and a 30-day share price return of 14.65%. Momentum has been supported by a 1-year total shareholder...

Endesa (BME:ELE) is in focus after reporting half year 2026 results, with sales of €10,807 million, revenue of €10,995 million and net income of €1,470 million, alongside higher earnings per share. See our latest analysis for Endesa. Endesa’s recent half year 2026 earnings update has arrived alongside solid momentum, with a 1 month share price return of 9.34% and a year to date share price return of 36.07%. The 1 year total shareholder return of 73.01% highlights how recent gains build on a...

The sudden arrival of 60,000 migrants into Spain’s Ceuta enclave has pushed border security, surveillance and regional stability into the spotlight. For investors, this kind of shock can quickly reshape how capital flows into Spanish defense and security stocks that are directly exposed to the news. Some companies may see stronger demand for their technology and services. Others could simply attract more attention as policies and budgets adjust. This article walks through 3 stocks from a...

The half-year results for Aena S.M.E., S.A. ( BME:AENA ) were released last week, making it a good time to revisit its...

ACS, Actividades de Construcción y Servicios, S.A. ( BME:ACS ) shareholders are probably feeling a little disappointed...

Amadeus IT Group stock has quietly ground higher in recent months, with a 3 month gain of about 8.9% and a close at €53.34 on 31 July. The market has been rewarding the story. The headline from this earnings release is more nuanced. Revenue for Q1 2026 sat at €1,682.6m and basic earnings per share were €0.83, while management kept free cash flow and margin discipline in clear focus. The real question now is whether that cash generation and margin profile justify the current P/E of 16.1x over...

Banco Bilbao Vizcaya Argentaria (BME:BBVA) stock is in focus after the bank reported second quarter 2026 net income of €3,062 million and announced a new €2b share buyback alongside higher regional guidance. See our latest analysis for Banco Bilbao Vizcaya Argentaria. Banco Bilbao Vizcaya Argentaria’s latest results and €2b buyback have landed after a strong run, with a 10.25% 1 month share price return and a 75.63% 1 year total shareholder return signalling strong momentum built over several...

It's been a good week for Viscofan, S.A. ( BME:VIS ) shareholders, because the company has just released its latest...

A week ago, Endesa, S.A. ( BME:ELE ) came out with a strong set of interim numbers that could potentially lead to a...

BBVA stock closed at €24.2 after the market weighed in on its Q2 2026 numbers that delivered a punchy headline. The group posted net income of €3.062b for the quarter and €6.051b for the first half, with return on tangible equity around the low 20s that management calls best in class among big European banks. Short term traders are focused on the recent double digit share price gains. Long term investors are looking at a bank combining strong profitability with rising loans and a growing...

Pharma Mar stock closed at €80.15 after the market absorbed its half year 2026 update, leaving investors weighing a flat near term share price against a very different earnings picture. The company delivered resilient recurring oncology revenues and stayed cash generative, yet quarterly profit slipped into a small loss of €0.972m even as trailing twelve month earnings from continuing operations reached €56.126m. The real story now sits on the longer horizon. Royalty growth, the Zepzelca...

Redeia Corporación went into this print priced for steadiness, with the stock roughly flat over the past quarter. The latest move around €15.32 shows investors still testing that slow growth, high income story. The headline from Q2 is a squeeze on profitability. Quarterly net income of €123.7 million sits below Q1, even as revenue holds at €458.4 million, and trailing net profit margins are softer than last year. For a regulated grid operator that many holders treat as a bond substitute,...

Cox Infrastructure Group shares came into this earnings print on the back foot, with the stock down around 6% over the past month, yet the headline story is not the share price. The real shock is on the income line. Over the last twelve months the company swung from profit to a loss of €56.8 million, even as revenue reached €1.53b. That profit squeeze is what the market is trying to price in today, and it sets the emotional tone for how investors will read the rest of this report. Concerned...

Almirall (BME:ALM) is in focus after reporting half year 2026 results on 24 July, alongside a reiteration of full year guidance for net sales growth of 9% to 12%. See our latest analysis for Almirall. The reiteration of guidance comes after a mixed year for Almirall’s share price, with a 7-day share price return of 4.75% and a year-to-date share price return down 11.16%. The 3-year total shareholder return of 39.16% shows stronger longer term momentum. If today’s update has you thinking about...

Ercros stock closed at €3.485, with recent returns barely moving the needle over the past week and month. The share price looks calm on the surface. The earnings print is anything but. Q2 revenue landed at €214.397 million and flipped the company back into profit with net income of €9.705 million, after a run of quarterly losses. For a chemicals producer that has been unprofitable over the last twelve months and is expected to stay that way in forecasts, this single profitable quarter stands...

Why Vidrala’s latest earnings matter for shareholders Vidrala (BME:VID) has moved back into focus after its half year 2026 earnings on 23 July, with rising profit, firmer margins and a clear reaffirmation of full year financial targets. For the six months to 30 June 2026, Vidrala reported sales of €755.04 million compared with €751.14 million a year earlier. Net income was €117.4 million against €107.84 million, with basic earnings per share at €3.36 versus €3.0667. See our latest analysis...

The European stock market has shown resilience, with the pan-European STOXX Europe 600 Index rising by 0.46% amid robust corporate earnings and geopolitical tensions impacting oil prices. As investors navigate these complex conditions, identifying stocks that may be trading below their intrinsic value can present opportunities for those seeking potential growth in a volatile environment.

How Enagás earnings set the context for the stock Enagás (BME:ENG) has just reported half year 2026 results, with sales of €444.63 million and net income of €126.91 million, both lower than the same period a year earlier. Basic and diluted earnings per share from continuing operations were €0.49, compared with €0.68 a year ago. This gives investors fresh information to reassess how the stock’s current price reflects these figures. See our latest analysis for Enagás. Since the H1 2026 earnings...

Banco de Sabadell (BME:SAB) has reported Q2 2026 results with total revenue of €1,396 million and net income of €624 million, setting the tone for how the rest of the year may shape up for shareholders. The company has seen quarterly revenue move from €1,362 million in Q4 2025 to €1,046 million in Q1 2026 and then to €1,396 million in Q2 2026, while basic EPS tracked at €0.0776 in Q4 2025 and €0.0705 in Q1 2026. This gives investors a clearer view of how the top and bottom lines are pacing...

Grifols recently reported that the first patients have been dosed in two Phase 3 trials to expand U.S. labels for its flagship immunoglobulin therapies, GAMUNEX-C and XEMBIFY, targeting secondary immunodeficiency in certain blood cancers and chronic inflammatory demyelinating polyradiculoneuropathy. This push to broaden indications for existing plasma-derived products highlights how Grifols is trying to deepen its presence in complex, chronic immune-related conditions where immunoglobulin...

Investors in Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) had a good week, as its shares rose 8.6% to close at...

Investors in Indra Sistemas, S.A. ( BME:IDR ) had a good week, as its shares rose 8.9% to close at €53.36 following the...

Vidrala, S.A. ( BME:VID ) shareholders are probably feeling a little disappointed, since its shares fell 5.3% to €86.00...

It's been a good week for Naturgy Energy Group, S.A. ( BME:NTGY ) shareholders, because the company has just released...